LTX-109
Also known as: LTX 109, LTX‑109, LTX109, Lytix‑109, Lytone
Source LTX-109 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
LTX-109 is a synthetic, amphiphilic peptidomimetic under investigation for topical and intranasal use. It is being studied primarily as a rapid, bactericidal agent to eradicate Staphylococcus aureus (both methicillin‑sensitive and methicillin‑resistant) from the nasal cavity and to treat superficial skin infections such as impetigo. Early clinical work also suggests activity against enveloped respiratory viruses.
Mechanism of Action
LTX‑109 mimics host‑defence peptides and inserts into microbial membranes, causing rapid disruption of lipid bilayers and loss of cellular integrity. In bacteria this leads to cell lysis, while in enveloped viruses it destabilises the viral envelope, rendering the particles non‑infectious. The membrane‑targeted action is non‑specific, which underlies its low propensity for resistance development.
What the Research Shows
Pre‑clinical studies demonstrated broad‑spectrum bactericidal activity and a prolonged post‑antibiotic effect (average 5.5 h) compared with mupirocin. In vitro serial‑passage experiments with diverse MRSA and MSSA isolates showed <4‑fold MIC shifts after 60 passages and no spontaneous resistance at 4–8 × MIC. A phase‑II nasal decolonisation trial reported significant reduction of MRSA/MSSA carriage after 2 days of 2‑5 % intranasal LTX‑109, with minimal reversible epithelial changes and very low systemic exposure. A 2026 antiviral study found that LTX‑109 reduced SARS‑CoV‑2 and influenza viral loads in cell culture and in a hamster model, supporting its broad‑spectrum envelope‑disrupting activity. Overall, the evidence is limited to early‑phase human studies and animal models.
Reported Benefits
Evidence indicates that LTX‑109 rapidly kills S. aureus on contact, achieves nasal decolonisation after a single day of treatment, and maintains activity without detectable resistance development in the strains tested. Its prolonged post‑antibiotic effect may allow less frequent dosing. Early safety data show low systemic absorption and only mild, reversible nasal irritation. The antiviral work suggests potential utility against enveloped respiratory viruses, although this remains pre‑clinical.
Limitations of the Evidence
LTX‑109 is still investigational; no regulatory approval exists for any indication. Human data are confined to a small nasal decolonisation trial, limiting confidence about efficacy across diverse populations and infection types. Resistance assessments involved a limited number of isolates, and long‑term resistance risk is unknown. The antiviral findings are limited to in‑vitro assays and a single animal model, without human clinical evidence. Formulation stability and large‑scale manufacturing have not been reported.
Safety Considerations
In the nasal decolonisation study, participants experienced minimal reversible epithelial lesions and no serious adverse events over a 9‑week follow‑up. Systemic exposure was negligible (Cmax 3.7–11.7 ng/mL) and the drug was undetectable in plasma after one week. No safety concerns were reported in the antiviral animal study, but human tolerability beyond short‑term nasal use has not been established. Potential for local irritation should be considered.
How It Is Administered
LTX‑109 has been formulated as a topical ointment or spray for intranasal application, typically at concentrations ranging from 1 % to 5 % for decolonisation protocols. The investigational regimen involved once‑daily dosing for up to three days. Topical skin formulations for impetigo are also under study. No oral or parenteral routes have been reported.
Routes of Administration
Goals & Uses
- Treatment of impetigoDermatology / Anti InfectiveModerate
- Skin and soft tissue infection (SSTI) treatmentDermatology / Anti InfectiveLow
- treat bacterial skin infectionsAntimicrobialModerate
- Prevention of MRSA surgical site infectionsInfection PreventionLow
- address antibiotic‑resistant pathogensAntimicrobialModerate
- MRSA nasal decolonizationAnti Infective / DecolonizationModerate
Contraindications
- Application to open wounds or mucous membranes beyond intended siteApplication Site SafetyModerate
- Known hypersensitivity to LTX-109 or excipientsAllergyHigh
- known hypersensitivity to LTX‑109 or formulation componentsAllergyHigh
Adverse Effects
- Local skin irritationDermatologicalCommon
- Erythema at application siteDermatologicUncommon
- Nasal irritationLocal/NasalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Contact dermatitisDermatologicalUncommon
- Application site burning or stingingLocal ReactionCommon
Drug Interactions
- topical antibioticsLow
- Other topical antimicrobials (e.g., mupirocin)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- pediatric use (<12 years)AgeRelative
- Patients with compromised nasal or skin integrityMedical ConditionRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical development under EMA guidance.
- United StatesInvestigationalPhase II/III trials ongoing.
- United KingdomInvestigationalUnder UK Medicines and Healthcare products Regulatory Agency review.
Not yet approved in any jurisdiction; currently in Phase II/III clinical trials for topical use.
Evidence & Sources
- Journal ArticleModerateSakr A, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleLowSingh B, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleLowSaravolatz LD, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateScott RW, Tew GN2017-01-01T00:00:00.000000Z
- Journal ArticleLowPagliari M, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateNilsson AC, et al.2015-01-01T00:00:00.000000Z
Frequently Asked Questions
What infections is LTX‑109 being studied for?
Current research focuses on intranasal decolonisation of methicillin‑sensitive and methicillin‑resistant Staphylococcus aureus and on topical treatment of superficial skin infections such as impetigo. Pre‑clinical work also suggests activity against enveloped viruses like SARS‑CoV‑2 and influenza.
Does LTX‑109 cause antibiotic resistance?
In vitro serial‑passage experiments with diverse MRSA and MSSA strains showed minimal changes in MIC values and no spontaneous resistance at concentrations up to eight times the MIC, indicating a low propensity for resistance development.
Is LTX‑109 safe for regular use?
Early clinical data report only mild, reversible nasal epithelial changes and very low systemic absorption after short‑term use. No serious adverse events were observed over a nine‑week follow‑up, but long‑term safety and broader population data are still lacking.
How is LTX‑109 applied?
The compound is delivered as a topical ointment or nasal spray. In the published decolonisation study, participants applied a 2 % or 5 % intranasal formulation once daily for up to three days.
Has LTX‑109 been approved for any medical use?
No. LTX‑109 remains an investigational agent and has not received regulatory approval for any indication. Ongoing clinical trials are evaluating its safety and efficacy.
What is LTX-109?
LTX-109 is a synthetic, amphiphilic peptidomimetic under investigation for topical and intranasal use. It is being studied primarily as a rapid, bactericidal agent to eradicate Staphylococcus aureus (both methicillin‑sensitive and methicillin‑resistant) from the nasal cavity and to treat superficial skin infections such as impetigo. Early clinical work also suggests activity against enveloped respiratory viruses.
What is LTX-109 used for?
LTX-109 is educationally associated with: Treatment of impetigo, Skin and soft tissue infection (SSTI) treatment, treat bacterial skin infections, Prevention of MRSA surgical site infections, address antibiotic‑resistant pathogens, MRSA nasal decolonization. Educational only — not medical advice.
How is LTX-109 administered?
Recorded routes of administration: Nasal, Topical.
What are the potential side effects of LTX-109?
Reported adverse effects include: Local skin irritation, Erythema at application site, Nasal irritation, Headache, Contact dermatitis, Application site burning or stinging. This list is not exhaustive — consult a qualified clinician.
Who should avoid LTX-109?
Recorded contraindications: Application to open wounds or mucous membranes beyond intended site, Known hypersensitivity to LTX-109 or excipients, known hypersensitivity to LTX‑109 or formulation components. Consult a qualified clinician before use.